Inhibikase Therapeutics, Inc. IKT
1.45 USD -0.07 (-4.61%)
Regular-session close
1.45 0.00 0.00%
After hours · Nov 16, 4:10 PM ET
1.45 Day range 1.57
1.40 52-week range 2.61
- YTD
- -29.27%
- 1 year
- -5.23%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $8 price target.
globenewswire.com Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…
